Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
Bowen Zhang, Chang Liu, Zhenqian Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11158-11186
Closed Access | Times Cited: 18

Showing 18 citing articles:

Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 24
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 15
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 13
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
Yulu Zhang, Annan Ming, Junyan Wang, et al.
Pharmacological Research (2024) Vol. 205, pp. 107234-107234
Open Access | Times Cited: 8
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 6
Structure–Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer
Maoxu Xiao, Si Ha, Jiacheng Zhu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5567-5590
Closed Access | Times Cited: 4
SKP1‐CUL1‐F‐box: Key molecular targets affecting disease progression
Xiangrong Zeng, Jiaying Cao, Juan Xu, et al.
The FASEB Journal (2025) Vol. 39, Iss. 2
Open Access
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
PROTAC technology for prostate cancer treatment
Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Discovery of Novel Rigid STING PROTAC Degraders as Potential Therapeutics for Acute Kidney Injury
Rui Ma, Renquan Fu, Yifan Wang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117539-117539
Closed Access
Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer
Wenqiang Zhang, Hao‐Jie Zhu, Zhuolin Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy
Si-Han Zhang, Yaowu Su, Mengzhu Zheng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117485-117485
Open Access | Times Cited: 2
PSMAx-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer
Xiao-Lei Meng, Xiaolin Hu, Siqi Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 1
N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review
Ye Chen, Tian Lan
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
Discovery of a Highly Potent, N-terminal Domain-targeting degrader of AR-FL/AR-V7 for the treatment of Prostate Cancer
Si Ha, Changwei Ji, Jiaqi Yang, et al.
European Journal of Medicinal Chemistry (2024), pp. 117079-117079
Closed Access
Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia
Xinfei Mao, Weitong Hu, Mingfei Wu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Page 1

Scroll to top